now browsing by category
Dr. Sameer Jejurikar is a brilliant, board-certified plastic surgeon based in Dallas, Texas. Known for his loving, compassionate manner of consulting with patients, Dr. Jejurikar wants to help each and every one of his patients achieve their new cosmetic goals. Dr. Sameer Jejurikar mainly focuses on the reconstruction of the face, eyes, nose, body, and breast in his extensive practice. To elaborate on his many fascinating skills, Dr. Sameer Jejurikar also specializes in several cosmetic procedures that include breast augmentations, tummy tucks, facelifts, liposuction, and even extensive reconstructive surgery such as hand surgery and microsurgery. Dr. Sameer Jejurikar has worked very hard over his many years in practice to give the best possible care and consideration to his patients.
Not only is Dr. Jejurikar an exceptional plastic surgeon and physician but he has quite the bedside manner with his patients. It seems that Dr. Jejurikar has been praised and recognized by his patients and in fact, he was honored by Patients’ Choice in 2012 with the Compassionate Doctor Certification. And in fact, only his patients can vote for him in order to give Dr. Jejurikar such an honor. And Dr. Jejurikar has most definitely earned such an honor since he practices what he preaches by being very generous of his time as well as his skills. Dr. Jejurikar donates his time and services to organizations such as Smile Bangladesh to help those in need internationally. It is without saying that Dr. Sameer Jejurikar seems to be a man of his word and his deeds when it comes to helping to change so many lives with his craft. Dr. Sameer Jejurikar has been in practice for almost 20 years and he seems to have no intention of stopping the magic that he does.
Oncotarget is now among the most popular peer-reviewed journals in the world. While the Journal was established focusing on oncology, it recently started accepting scientific papers from other medical fields as well. The journal is open source, which means that it is accessible by anybody from any corner of the globe. The journal has greatly benefited researchers and clinicians by offering a platform where they share scientific breakthroughs with the rest of the world. Those who seek to contribute to the journal can submit their papers, which are peer-reviewed. The scientific papers also pass through an experienced team of editors-in-chief who ensure that they conform to the standards set by COPE.
Every paper published on oncotarget goes through many checks to prove its authenticity and conformance to the set standards. The published work must also be of value to the users by contributing to the scientific body of knowledge. The oncotarget journal is currently accepting papers in numerous fields that include Endocrinology, Neuroscience, cardiology, pharmacology, cell biology, metabolism, and many more. Check Oncotarget at scimagojr.com
A lot of indicators are pointing to the fact that oncotarget is set to grow more popular in the coming days. Recently, the journal recorded an increase in its impact factor during the new ranking by Thompson Reuters. The increase in the number of topics has also increased the number of people accessing the journal.
There is a host of in-depth topics related cancer that are covered in the journal. The number of articles and scientific breakthroughs published on oncotarget continues to grow every other day. The journal was established in 2010 by Mikhail and Andrei with the main focus being oncology. Dr. Mikhail and Andrei Gudkov are accomplished researchers who have conducted extensive research on oncology for many years. They decided to establish the journal in a bid to enhance the accessibility of critical scientific information within the shortest time possible. Follow Oncotarget on Linkedin.
Because the study of oncology covers a wide area and there are many interested parties, Oncotarget has established a new podcast series that ensures that scientific breakthroughs reach the general audience. The journal has set up a blog for individuals who want to keep abreast with the newest developments in the medical arena.
— Oncotarget (@OncotargetJrnl) December 12, 2017